Search

Objective: To assess whether blood type was associated with diminished ovarian reserve (DOR) (day-3 follicle-stimulating hormone level >10 IU/L), controlling for history of tobacco smoking, body mass index (BMI), history of endometriosis, ovarian surgery, previous pregnancy, and maternal age., Design: Cross-sectional study., Setting: Academic medical center, Division of Reproductive Endocrinology and Infertility., Patient(s): Women undergoing in vitro fertilization (IVF) from 2006-2011 (n = 305)., Intervention(s): None., Main Outcome Measure(s): Presence of DOR in relation to a patient's blood type., Result(s): Other investigators have reported an increased risk for DOR in patients with blood type O and a protective effect on ovarian reserve for blood type A. We observed no association between a woman's blood type and DOR. We found an increased risk for DOR in patients aged 35 and older. Obesity (BMI ≥ 30 vs. BMI <25) was associated with lower odds of DOR., Conclusion(s): In comparison with blood type A, blood type O is not associated with an increase in DOR. We found no clinical implications for using blood type as a risk factor for DOR., (Copyright © 2013 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.)

A retrospective cohort study was performed to evaluate IVF clinical pregnancy rates and livebirth rates between patients receiving progesterone supplementation through the first trimester of pregnancy (first trimester protocol) at 12 weeks vs. discontinuation after a positive beta-hCG test 2 weeks after retrieval (luteal protocol) at 4 weeks of pregnancy. A similar rate of clinical pregnancies occurred at 7 weeks (81.8% luteal protocol vs. 85.8% first trimester protocol; P=.49) and for livebirth rates (76.8% luteal protocol vs. 75.0% first trimester protocol; P=.80), but a trend toward a higher rate of pregnancy loss after 7 weeks in the first trimester protocol group occurred (15.5% vs. 4.4%; P=.06), indicating that first trimester progesterone supplementation may support early pregnancy through 7 weeks by delaying miscarriage but does not improve livebirth rates.